Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage

• Váldodahkkit: Bushra Khan (Dahkki), Rowaid M. Qahwaji (Dahkki), Mashael S. Alfaifi (Dahkki), Mohammad Mobashir (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2024-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Combining immune checkpoint inhibitors, specifically nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), holds substantial promise in revolutionizing cancer treatment. This review explores the transformative impact of these combinations, emphasizing their potential for enhancing therapeutic outcomes...